Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of mesdopetam

Trial Profile

Phase III trial of mesdopetam

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesdopetam (Primary)
  • Indications Parkinson's disease; Psychotic disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Mar 2024 According to IRLAB Therapeutics AB media release, Based on the positive feedback from the FDA, company will now engage with European regulatory agencies in accordance with standard practice before initiation of the Phase III program.
    • 22 Mar 2024 According to IRLAB Therapeutics AB media release, company today announced receipt of written minutes from a recent End-of-Phase 2 meeting for mesdopetam with the US Food and Drug Administration, FDA. The minutes confirm previously communicated positive verbal feedback from meeting. At the End-of-Phase 2 meeting with the FDA, aspects related to all parts of development plan for mesdopetam, including the design of a Phase III program, were evaluated and commented upon.
    • 03 Jan 2024 According to IRLAB Therapeutics AB media release, company is working together with US advisory groups Clintrex, a clinical and regulatory strategy advisor and ProPharma Group (PPG), regulatory agent in the US, to develop the strategy for the mesdopetam Phase III program.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top